Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 02/20/2026 | PUT | $280.00 | 156 | +150 | +2,500.00% |
| 02/20/2026 | CALL | $350.00 | 150 | +149 | +14,900.00% |
| 11/21/2025 | CALL | $260.00 | 158 | +2 | +1.28% |
| 11/21/2025 | PUT | $260.00 | 151 | +1 | +0.67% |
| 02/20/2026 | CALL | $270.00 | 2 | +1 | +100.00% |
| 09/19/2025 | CALL | $340.00 | 4 | +1 | +33.33% |
| 02/20/2026 | CALL | $480.00 | 0 | 0 | |
| 02/20/2026 | CALL | $490.00 | 0 | 0 | |
| 02/20/2026 | PUT | $460.00 | 0 | 0 | |
| 02/20/2026 | PUT | $470.00 | 0 | 0 | |
| 02/20/2026 | PUT | $480.00 | 0 | 0 | |
| 02/20/2026 | PUT | $490.00 | 0 | 0 |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Zymeworks Announces Participation in Upcoming Investor Conferences
08/19 06:00 am
GlobeNewswire Inc.
Read moreZymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
07/17 06:00 am
GlobeNewswire Inc.
Read moreWaldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight
07/14 01:00 pm
GlobeNewswire Inc.
Read moreAscentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
07/07 07:30 pm
GlobeNewswire Inc.
Read moreZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
05/30 06:00 am
GlobeNewswire Inc.
Read moreBlood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
05/12 01:00 pm
GlobeNewswire Inc.
Read moreWhy Summit Therapeutics Rocketed Double-Digits Today
04/23 04:05 pm
The Motley Fool
Read moreZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
04/17 06:00 am
GlobeNewswire Inc.
Read moreBeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
04/03 11:19 am
Benzinga
Read moreChina-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
03/04 09:37 am
Benzinga
Read moreAdvanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
03/03 02:00 pm
GlobeNewswire Inc.
Read moreZymeworks Announces Participation in Upcoming Investor Conferences
02/25 07:00 am
GlobeNewswire Inc.
Read moreAlibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
02/23 11:05 am
Benzinga
Read moreZymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
02/13 07:00 am
GlobeNewswire Inc.
Read moreOrphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth
02/03 05:52 am
GlobeNewswire Inc.
Read moreIndaptus Therapeutics Provides Year-End Review and Outlook for 2025
01/08 09:00 am
GlobeNewswire Inc.
Read more